Aim: To assess the diagnostic accuracies of APRI and FIB4 in predicting various stages of liver fibrosis in patients with NAFLD and their correlation with Fibroscan. Materials and methods: The current investigation was a prospective, observational study done among 50 patients with non-alcoholic fatty liver disease (NAFLD). The patients were identified using ultrasound imaging and both males and females were included in the study. All patients who were diagnosed with non-alcoholic fatty liver disease (NAFLD) were included in this research. The laboratory test results that were evaluated included those in the hospital information. All results were obtained within one month of a Fibroscan examination. Results: Mean APRI and FIB-4 among the study subjects was 0.89±0.12 and 1.59±0.45 respectively. NAFLD fibrosis was reported among 48% of the subjects i.e. G1, G2, G3 and G4 was revealed in 24%, 8%, 10% and6% of the subjects respectively. Based on FibroScan results, 50% were classified as F1, 32% as F2, 12% as F3 and 6% as F4. Mean AST/ALT, APRI and FIB-4 was found to be more in F3+F4grade as compared to F1+F2 grade. When mean AST/ALT, APRI andFIB-4 was compared according to fibroscan results, significant difference was found w.r.t. APRI and FIB-4 as p<0.05. FIB-4 has the best sensitivity while APRI has the best specificity in predicting different stages of liver fibrosis among patients of NAFLD. Hence APRI and FIB-4 was comparable in this study to predict liver fibrosis. AST/ALT has the worst sensitivity and specificity in predicting different stages of liver fibrosis among patients of NAFLD. Conclusion: Our findings indicate that APRI is the most effective marker for predicting advanced liver fibrosis, surpassing the AST/ALT ratio and showing similar performance to FIB-4. Additionally, APRI exhibits the highest connection with FibroScan results. Thus, in situations where there are limited resources and FibroScan is not accessible, APRI serves as a suitable indicator for predicting significant liver fibrosis.